Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Singular Genomics Systems

Explore full profile

Accelerating genomics for the advancement of science and medicine

San Diego, United StatesFounded 2016Biotech & Life Sciences
Revenue $1–10M Latest reported FY

About Singular Genomics Systems

Singular Genomics, founded in 2016 by Drew, is a biotechnology company based in San Diego, California. The company focuses on advancing genomics, which is the study of an organism's complete set of DNA, including all of its genes. Singular Genomics aims to accelerate scientific and medical research by providing innovative tools and technologies for genomic sequencing.

The company serves a variety of clients, including academic researchers, pharmaceutical companies, and clinical laboratories. These clients use Singular Genomics' products to conduct multiomic research, which involves studying various types of biological data, such as DNA, RNA, and proteins, to understand complex biological systems and diseases.

Singular Genomics operates in the genomics market, which is a rapidly growing sector within the broader biotechnology industry. The company's flagship product is the G4 sequencing platform, an ultra-high throughput, high-resolution spatial sequencing system. This platform allows researchers to process multiple samples simultaneously, making it faster and more efficient to conduct large-scale genomic studies.

The business model of Singular Genomics revolves around selling its sequencing platforms and related consumables, such as flow cells, which are essential components used in the sequencing process. The company generates revenue by selling these products to its clients, who rely on them for their research and clinical applications.

In summary, Singular Genomics is a forward-thinking biotech company dedicated to advancing genomics through innovative sequencing technologies. By providing high-performance tools for genomic research, the company supports the scientific and medical communities in their efforts to understand and treat complex diseases.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2016
Headquarters
San Diego, United States
Listing
IPO 2021
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Domain Associates

Series A4 investors entered at this stage

Series B and later5 investors entered at this stage

Employees mapped 151 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 9 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States99.3%
🇲🇽 Mexico0.7%
2 countries shown
Web traffic by country
3.5K monthly visits
across markets
🇺🇸 United States94.3%
🇯🇵 Japan5.7%
Top 2 markets shown

Patents

Estimated portfolio value
$27M

111 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Singular Genomics Systems on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Singular Genomics Systems on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.